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Edited by Vladimir SkulachevAbstract Intact osteoactivin, a novel type I membrane glyco-
protein, were shed at a dibasic motif in the juxtamembrane re-
gion in C2C12 myoblasts. Extracellular fragments were
secreted into the culture media by a putative metalloprotease.
Extracellular fragments of osteoactivin, but not control protein,
induced matrix metalloprotease-3 (MMP-3) expression in NIH-
3T3 ﬁbroblasts. Epidermal growth factor (ERK) kinase inhibi-
tors inhibited the osteoactivin-mediated MMP-3 expression,
whereas the extracellular fragment of osteoactivin activated
ERK1/2 and p38 in the mitogen-activated protein kinase path-
way. Our results suggest that the extracellular fragments of
osteoactivin produced by shedding act as a growth factor to in-
duce MMP-3 expression via the ERK pathway in ﬁbroblasts.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Keywords: C2C12 myoblasts; ERK1/2; NIH-3T3 ﬁbroblasts;
Osteoactivin; Shedding1. Introduction
Membrane proteins can be proteolytically cleaved at their
juxtamembrane region, in a process called ectodomain shed-
ding, which results in detachment of their extracellular region.
Several studies have demonstrated that ectodomain shedding
could result in the release of cytokines or growth factors from
their membrane-bound precursors to upregulate the prolifera-
tion of and protein synthesis in the surrounding cells [1–3]. OnAbbreviations: ADAMs, a disintegrin and metalloproteases; ANOVA,
one-way analysis of variance; BDF1 mice, (C57BL/6xDGA/2)F1 mice;
DMEM, Dulbecco’s modiﬁed Eagle’s medium; DMSO, dimethylsulf-
oxide; EGF, epidermal growth factor; ERK, extracellular signal-
regulated kinase; FGF-2, ﬁbroblast growth factor-2; GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase; IL-1, interleukin-1; JNK, c-
Jun N-terminal kinase; MAPK, mitogen-activated protein kinase;
MMP-3, matrix metalloproteinase-3; MS, mass spectrometry; RT-
PCR, reverse transcription and polymerase chain reaction; TNF-a,
tumor necrosis factor-a
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doi:10.1016/j.febslet.2007.11.036the other hand, we have reported previously that unloading
stress, e.g., denervation and tail-suspension, induced the
expression of osteoactivin, a type I membrane glycoprotein,
in myoﬁbers [4], and that osteoactivin upregulated the expres-
sion of matrix metalloprotease-3 (MMP-3) in ﬁbroblasts inﬁl-
trating skeletal muscles during unloading [4]. In such case, the
expression of MMP-3 was induced in not only myoﬁbroblasts
adjacent to myoﬁbers of the skeletal muscle but also in distant
myoﬁbroblasts. Furthermore, the extracellular fragment of re-
combinant osteoactivin was capable by itself to induce the
expression of MMP-3 in NIH-3T3 ﬁbroblasts [4]. Based on
these ﬁndings, we hypothesized that osteoactivin was cleaved
on the plasma membrane (shedding), resulting in the release
of the extracellular fragment, which interacted with ﬁbroblasts.
MMP-3 is a key protease known to regulate regeneration/
degeneration of extracellular matrix based on its broad sub-
strate speciﬁcity, compared with other metalloproteases. A
variety of growth factors and cytokines, including ﬁbroblast
growth factor-2 (FGF-2), epidermal growth factor (EGF)
and interleukin-1 (IL-1), regulate MMP-3 expression through
activation of the mitogen-activated protein kinase (MAPK)
pathway [5]. Therefore, it is important to examine the stimula-
tory eﬀects of osteoactivin on the MAPK signaling molecules
for MMP-3 expression.
The present study was designed to ascertain the ectodomain
shedding of osteoactivin and determine the intracellular signal-
ing in the MAPK pathway involved in osteoactivin-induced
expression of MMP-3. Interestingly, unloading stress, such as
denervation, induced ectodomain shedding of osteoactivin in
hindlimb skeletal muscle. Furthermore, the extracellular frag-
ment of osteoactivin produced by the shedding stimulated the
extracellular signal-regulated kinase (ERK) pathway, resulting
in upregulated expression of MMP-3. Our results suggest that
osteoactivin is an important growth factor that originates from
skeletal muscle cells in response to unloading stress.2. Materials and methods
2.1. Animals and sciatic nerve denervation
Adult male (C57BL/6xDBA/2)F1 (BDF1) mice (9-week-old),
weighing 18–22 g, were purchased from Japan SLC (Shizuoka, Japan).
Osteoactivin-transgenic mice were prepared and back-crossed withblished by Elsevier B.V. All rights reserved.
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under speciﬁc pathogen-free conditions at 23 ± 2 C on a 12:12-h
light-dark cycle and allowed free access to food and water. For the
denervation procedure, the dorsal skin of the right thigh was cut and
the posterior muscles were divided to expose the sciatic nerve. Chronic
denervation was produced by cutting a 5-mm segment of the right sci-
atic nerve [6]. All animal experiments were performed according to the
Guide for the Care and Use of Laboratory Animals at The University
of Tokushima. The experiments performed in this study were approved
by the Animal Care and Use Committee of The University of Tokushi-
ma School of Medicine.
2.2. Cell culture, transfection and protease inhibitor treatment
Mouse myoblastic C2C12 cells and ﬁbroblastic NIH-3T3 cells were
purchased from Dainippon Pharmaceutical (Osaka, Japan). The cells
were maintained and allowed to proliferate at 37 C with 5% CO2/
95% air in 4 ml of Dulbecco’s modiﬁed Eagle’s medium (DMEM), sup-
plemented with 10% fetal calf serum, 100 U/ml penicillin, and 0.1 mg/
ml streptomycin.
The expression vector of C-terminally V5/His-tagged mouse osteoac-
tivin was constructed and transfected with FuGene6 (Roche Diagnos-
tics, Mannheim, Germany) into C2C12 cells, as described previously
[4]. Vehicle (dimethylsulfoxide; DMSO) or a protease inhibitor, e.g.,
10 lM GM6001, a metalloprotease inhibitor (Calbiochem, San Diego,
CA), 100 nM epoxomicin, a proteasome inhibitor (Peptide Institute,
Osaka, Japan), or 25 lM E-64d, a cysteine protease inhibitor (Taisho
Pharmaceutical Co., Omiya, Japan), was added to the medium 24 h
after the transfection. Cycloheximide (100 lg/ml) was added at 3 h
prior to the treatment with vehicle or a protease inhibitor.
2.3. Immunohistochemical analyses
C2C12 cells cultured on coverslips were transfected with osteoactivin
gene and treated with either 10 lMGM6001 or vehicle (DMSO) as de-
scribed above. Then, immunocytochemical analysis was performed as
described previously [4]. The cells were incubated in the presence of
mouse anti-V5 IgG (1:2000 dilution) (Invitrogen, Carlsbad, CA) and
rabbit anti-cathepsin D IgG (1:1000 dilution), which was prepared as
described previously [7]. The bound antibodies were visualized with
Alexa 488-conjugated anti-mouse IgG and Alexa 568-conjugated
anti-rabbit IgG antibodies (dilution 1:600, Molecular Probes, Eugene,
OR). The slides were observed with the Leica TCS-NT confocal micro-
scope system (Wetzlar, Germany).
Immunohistochemical analysis of denervated mouse gastrocnemius
muscle was performed by indirect immunoﬂuorescence methods using
rat anti-mouse a disintegrin and metalloprotease 12 (ADAM12)
(Chemicon International, Tokyo, Japan) and anti-mouse MMP-3 anti-
bodies (Sigma, St. Louis, MO), as described previously [4].
2.4. Subcellular fractionation
Osteoactivin-transfected C2C12 cells were treated with vehicle or
100 nM epoxomicin for 3 h. Then, the cells were further cultured over-
night in the presence of 50 lM E-64d and 50 lM pepstatin A (Sigma)
to increase the density of lysosomes. They were subjected to subcellular
fractionation as described previously [8]. Brieﬂy, the collected cells in a
homogenization buﬀer [5 mM sodium phosphate buﬀer, pH 7.2, con-
taining 0.25 M sucrose and 1 tablet/25 ml of a cocktail of protease
inhibitors (Roche Diagnostics, Mannheim, Germany)] were homoge-
nized by a Dunce’s glass homogenizer. After removing unbroken cells
and nuclei, the homogenate was centrifuged at 18500 · g for 30 min.
The pellet was designated as the lysosome-mitochondria fraction.
The supernatant was subjected to ultracentrifugation at more than
100000 · g for 1 h to remove microsome proteins.
2.5. Treatment with recombinant extracellular fragment of osteoactivin
and MAPK inhibitors
The recombinant extracellular fragment of osteoactivin and LacZ
protein were prepared as described previously [4]. NIH-3T3 cells at
60% conﬂuence were treated with 25 nM (ﬁnal concentration) of the
recombinant extracellular fragment of osteoactivin or LacZ (control)
and cultured for the indicated times. In some experiments, the cells
were preincubated with vehicle (DMSO), 10 lM PD98059, an ERK1
kinase inhibitor, 5 lM U0126, an ERK1/2 kinase inhibitor or 10 lM
SB203580, a p38 inhibitor (Calbiochem), for 30 min prior to treatment
with osteoactivin or LacZ.2.6. Western blotting
Cells were lysed with 50 mM Tris–HCl buﬀer, pH 7.5, 150 mM
NaCl, 1% TritonX-100, and 1 tablet/25 ml of a cocktail of protease
inhibitors. In some cases, the lysates were treated with 100 mU endo-
glycosidase F or 20 mU endoglycosidase H (Sigma) as described previ-
ously [9]. Cell lysates (25 lg protein/lane) or condition medium (15 ll/
lane) were subjected to western blotting as described previously [4].
The following primary antibodies were used: anti-V5 (Invitrogen),
anti-osteoactivin (R&D Systems, Minneapolis, MN), anti-a-tubulin
(Sigma), anti-b-actin (Oncogene Research Products, San Diego, CA),
anti-phosphorylated MAPK, and anti-MAPK (Cell Signaling Tech-
nology, Danvers, MA) antibody. The bound antibodies were detected
with the suitable secondary antibodies and the enhanced chemilumi-
nescence system (Amersham Biosciences, Little Chalfont, UK). The
protein concentration of each sample was measured by the Lowry’s
method [10].
2.7. Real-time reverse transcription and polymerase chain reaction (RT-
PCR)
Total RNA was extracted from cells with an acid guanidinium thio-
cyanate–phenol–chloroform mixture (Isogen; Nippon Gene, Tokyo,
Japan). Real-time reverse transcription and polymerase chain reaction
(RT-PCR) was performed with the primers and SYBR Green dye by
using a real-time PCR system (model ABI 7300, Applied Biosystems,
Foster City, CA), as described previously [4]. The following primers
were used for ampliﬁcation: 5 0-CGTGTTCCTACCCCCAATGT-30
and 5 0-ATGTCATCATACTTGGCAGGTTTCT-3 0 for mouse glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH); 5 0-TGGAGATGC-
TCACTTTGACG-3 0 and 5 0-GCCTTGGCTGAGTGGTAGAG-3 0
for mouse MMP-3; 5 0-ACCATCCCAACGTACAGAGC-3 0 and
5 0-GCTGTTGTGCAGAGGTTCAA-30 for mouse ADAM9; 5 0-AG-
AGAAAGGAGGCTGCATCA-3 0 and 5 0-GCCTGCTTGACCTCT-
GGTAG-30 for mouse ADAM12.
2.8. Microsequencing
To identify the shedding point of osteoactivin, a microsequencing
processing by Edman degradation was performed [11]. The single band
containing C-terminal fragment (20 kDa) of osteoactivin was cut from
the gel after electrophoresis. The protein was extracted from the gel
and reduced with 100 ml of 50 mM Tris–HCl, pH 8.5, containing
10% acetonitrile, 5 mM EDTA, and 7 mM dithiothreitol for 1 h at
45 C. After being cooled to room temperature, the solution was alkyl-
ated with 10 ll of 200 mM iodoacetate for 20 min at room temperature
in the dark. The extracted protein was sequenced on a sequencer
(477A, Applied Biosystems) equipped with an online phenylthiohydan-
toin analyzer.
2.9. Statistical analysis
The experimental data were expressed as means ± S.D. for four ani-
mals per group and statistically evaluated by using one-way analysis of
variance (ANOVA) with SPSS software (release 6.1; SPSS Japan, To-
kyo). Individual diﬀerences between groups were assessed by using
Duncan’s multiple range test. Diﬀerences were considered signiﬁcant
at P < 0.05.3. Results
3.1. Detection of osteoactivin shedding in vitro and in vivo
When V5-tagged osteoactivin was overexpressed in C2C12
myoblasts, we detected a fragment with a molecular mass of
20 kDa, in addition to its intact forms with molecular masses
of 97 and 116 kDa (Fig. 1A). In the presence of cycloheximide,
the amounts of both the intact form of osteoactivin and its
fragments decreased in a time-dependent manner. Since the
V5 sequence is linked to the C-termini of osteoactivin, the
20-kDa fragment was considered the C-terminal-truncated
form of osteoactivin. Treatment with endoglycosidases H
and F reduced the intact forms to bands of molecular masses
of 67 kDa (Fig. 1B), corresponding to the molecular mass of
H. Furochi et al. / FEBS Letters 581 (2007) 5743–5750 5745the non-glycosylated form [4]. Thus, due to high mannose-type
glycosylation, the intact forms of osteoactivin appeared with
broad bands ranging from 97 and 116 kDa. The extracellular
fragments of osteoactivin with molecular masses of 90 and
100 kDa accumulated in the media containing 24-h cultured
osteoactivin-transfected C2C12 myoblasts, while no such frag-
ments were identiﬁed in the media containing mock-transfec-
ted C2C12 myoblasts (Fig. 1C).
We also examined whether a similar cleavage of osteoactivin
occurred in the gastrocnemius muscle of sciatic nerve-dener-
vated transgenic mice. Only the intact forms of osteoactivin
of molecular masses of 97 and 116 kDa were detected in the
gastrocnemius muscle of osteoactivin-transgenic mice before
and denervation (Fig. 1D). We could not detect the two extra-
cellular fragments (90 and 100 kDa), although the amounts of
the intact forms (97 and 116 kDa) gradually decreased after
denervation. In contrast, denervation resulted in accumulation
of a 20-kDa-protein, the C-terminal-truncated form of osteo-
activin, in the gastrocnemius muscle after Day 10 (Fig. 1D),
indicating that denervation induced ectodomain shedding of
osteoactivin in the gastrocnemius muscle. However, it ap-
peared that the secreted extracellular fragments were easily di-
luted and/or degraded in skeletal muscle in vivo.0 31 6 9
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vent the shedding, but it resulted in accumulation of an addi-
tional fragment with a molecular mass of 14 kDa. In contrast,
E-64d, a cysteine protease inhibitor, did not aﬀect the shedding
of osteoactivin, although it prevented the degradation of the
C-terminal fragment (molecular mass of 20 kDa) produced
by the shedding.
Western blotting of the conditioned media obtained from
cultures of osteoactivin-transfected C2C12 cells treated with
the vehicle (DMSO) or 10 lMGM6001 for the indicated times
showed a time-dependent accumulation of extracellular frag-
ments of osteoactivin (Fig. 2B). GM6001 signiﬁcantly reduced
such accumulation. These results indicate that the extracellular
fragments of osteoactivin were cleaved by metalloproteases
and secreted into the conditioned media. We also conﬁrmed
these results by subcellular fractionation and immunocyto-
chemical analysis. Subcellular fractionation of E-64d- and
epoxomicin-treated C2C12 cells showed the presence of intra-
cellular fragments I and II of osteoactivin in the lysosomal and
cytosolic fractions, respectively (Fig. 2C). Analysis of double-
staining immunocytochemistry with anti-V5 and anti-cathep-
sin D antibodies showed accumulation of V5-positive frag-
ments (C-terminal fragment of osteoactivin) in the lysosomes
of osteoactivin-expressing C2C12 cells (Fig. 2D, a–c).
GM6001 inhibited such accumulation (Fig. 2D, d–f); in
GM6001-treated C2C12 cells, osteoactivin was mainly located
on the plasma membrane, which was stained with rabbit anti-
caveolin antibody (BD Bioscience, Bedford, MA) (data not
shown).
Among the membrane-bound metalloproteases, ADAM12
and ADAM9 have been reported to be associated with ectodo-
main shedding during myogenesis [12,13]. Therefore, we exam-
ined the expression of these ADAMs in the mouse
gastrocnemius muscle before and after denervation. Real-time
RT-PCR showed that denervation signiﬁcantly increased the
expression level of ADAM12 mRNA, but not that of ADAM9
mRNA (Fig. 2E), indicating that ADAM12 may account for
the shedding of osteoactivin in skeletal muscle cells. Further-
more, double staining of ADAM12 and MMP-3 showed that
the location of ADAM12, a membranous metalloprotease,
was distinct from that of MMP-3 in denervated mouse skeletal
muscle (Fig. 2F). Since we previously reported that induced
MMP-3 was present in ﬁbroblast-like cells inﬁltrated into
denervated mouse gastrocnemius muscle [4], extracellular frag-
ment of osteoactivin produced by shedding may induce expres-
sion of MMP-3 in ﬁbroblast-like cells. Fig. 2G provides a
summary of the results shown in Fig. 2A–F.
3.4. Extracellular fragments of osteoactivin induce upregulation
of MMP-3 mRNA expression in mouse ﬁbroblasts via ERK
pathway
A recombinant extracellular fragment of osteoactivin signif-
icantly increased the MMP-3 mRNA expression level com-
pared with LacZ (Fig. 3A). The amounts of MMP-3 mRNA
reached a peak value at 6 h after the treatment but gradually
decreased thereafter. According to changes in MMP-3 mRNA
expression, the amount of MMP-3 protein in NIH-3T3 ﬁbro-
blasts gradually increased after the addition of the recombi-
nant extracellular fragment of osteoactivin (Fig. 3A).
However, the conditioned medium of 2- or 3-day cultures of
osteoactivin-transfected C2C12 cells failed to induce MMP-3expression in NIH-3T3 ﬁbroblasts (Fig. 3B). At least 25 nM
of recombinant osteoactivin was required for the induction.
Western blotting of conditioned media revealed that transfected
C2C12 cells produced insuﬃcient amounts of osteoactivin to
induce MMP-3 expression (Fig. 3B). We next explored the
possible involvement of the MAPK pathway in osteoactivin-
mediated expression of MMP-3. For this purpose, we exam-
ined the phosphorylation (activation) of MAPKs, such as
ERK, p38 and JNK, and investigated the eﬀects of MAPK
inhibitors on MMP-3 expression in NIH-3T3 cells treated with
the recombinant extracellular fragment of osteoactivin. Treat-
ment with the recombinant fragment of osteoactivin increased
ERK1/2 and p38 phosphorylation in a time-dependent man-
ner, while phosphorylation of JNK was not detected even after
the treatment (Fig. 3C). The change in phosphorylation of
ERK1/2 and p38 paralleled that of MMP-3 expression; maxi-
mal phosphorylation of ERK1/2 and p38 requires at least 30-
min incubation with the recombinant extracellular fragment of
osteoactivin. In other experiments, PD98059, an inhibitor of
ERK1 kinase, and U0126, an inhibitor of ERK1/2 kinase, sig-
niﬁcantly inhibited osteoactivin-mediated MMP-3 expression
in NIH-3T3 cells (Fig. 3D). However, SB203580, an inhibitor
of p38, did not change MMP-3 expression in NIH-3T3 cells
treated with a recombinant extracellular fragment of osteoac-
tivin.4. Discussion
Ectodomain shedding is mediated by sheddases, such as
ADAMs and membrane-bound MMPs [1–3]. We demon-
strated in the present study the shedding of osteoactivin both
in vitro and in vivo. Shedding of osteoactivin in skeletal mus-
cles of mice required unloading stress, such as denervation,
while overexpression of osteoactivin in C2C12 cells was suﬃ-
cient for induction of ectodomain shedding of osteoactivin.
Based on these ﬁndings, we hypothesize that unloading stress
upregulates the expression of sheddases. In fact, denervation
increased the amounts of ADAM12 transcripts, but not
ADAM9 mRNA, in skeletal muscles. Furthermore, a broad
inhibitor against these sheddases signiﬁcantly prevented the
shedding of osteoactivin. These results suggest that ADAM12
is a potential candidate factor responsible for the unloading-
mediated ectodomain shedding of membrane proteins. How-
ever, our microsequencing of C-terminal fragment I revealed
that osteoactivin was cleaved at a dibasic motif in the juxta-
membrane region. There is no evidence, to our knowledge, that
ADAM12 can cleave membrane proteins at the dibasic motif,
although several other ADAMs, such as ADAM17 (tumor
necrosis factor-a; TNF-a converting enzyme) has been re-
ported to shed fractalkine (a CX3CL1 chemokine) at the diba-
sic site [14]. Therefore, we cannot exclude the possibility that
ADAMs other than ADAM12 contribute to the shedding of
osteoactivin. Further studies are needed to elucidate the path-
ophysiological roles of osteoactivin-mediated MMP-3 expres-
sion in matrix remodeling, especially the identiﬁcation and
characterization of sheddase speciﬁc for osteoactivin.
The present study also showed that the ectodomain shedding
of osteoactivin contributed, at least in part, to MMP-3 expres-
sion in myoﬁbroblasts after denervation. MMP-3 regulates the
growth and development of skeletal muscles by degradation of
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of matrix proteins, for instance proteoglycan [16], laminin [17]
and pro-MMPs [18]. Furthermore, targeted disruption of the
MMP-3 gene in mice caused a delay in wound healing due
to a failure in ﬁbroblast contraction [19,20], and synthetic
MMP inhibitors tested in clinical trials had reversible musculo-
skeletal toxicity as the main side eﬀect [21]. We demonstrated
previously that osteoactivin upregulated the expression of
MMP-3 and MMP-9 in ﬁbroblasts inﬁltrating the denervated
skeletal muscle in mice, and resulted in protection against se-
vere degeneration of skeletal muscle often seen in long-term
degeneration [4,22]. The osteoactivin-mediated upregulation
of MMPs in skeletal muscles may be a cytoprotective response
to injuries, such as denervation.
Our results implied that ERK activation plays an important
role in the osteoactivin-mediated expression of MMP-3 in ﬁbro-
blasts, because only the inhibition of ERK1/2 resulted in the
suppression of MMP-3 expression. ERK signaling is an impor-
tant pathway that mediates extracellular signals, such as cyto-
kines and growth factors, to nuclear transcription of MMP-3.
For example, FGF-2 and EGF induced MMP-3 expression in
endothelial cells and ﬁbroblasts, respectively, through the acti-
vation of the ERK pathway [23,24]. TNF-a and IL-1 increased
the amount of MMP-3 transcripts in synoviocytes through the
activation of p38 or c-Jun N-terminal kinase (JNK) signaling
[25,26]. Based on these ﬁndings, osteoactivin could be func-
tionally divided into the FGF and EGF families to stimulate
ERK signaling in inﬁltrated ﬁbroblasts into skeletal muscle
and bone. Since the extracellular domain of osteoactivin has
a heparin-binding motif, ﬁbroblasts may have a heparin sulfate
proteoglycan-type receptor for osteoactivin, similar to FGF
receptor. We are under further examination to identify osteo-
activin receptor.
The biological eﬀects of ERK1/2 are mediated by down-
stream phosphorylation of nuclear transcription factors.
Among them, the signal inducible transcriptional factor activa-
tor protein-1 (AP-1) has been implicated as a major down-
stream eﬀector for ERK1/2, because the AP-1 binding site
was identiﬁed in the promoter of collagenase (MMP-1) gene
[5,27], and EGF receptor-mediated migration and invasion
have been also linked to the activity of the AP-1 transcription
factor [28]. AP-1 is one of the most important downstream
substrates of ERK1/2 signaling that mediate MMP-3 expres-
sion induced by osteoactivin, since there are at least two AP-
1 binding sites at the 5 0-franking promoter region of mouse
MMP-3 gene [29]. Further studies are necessary to elucidate
this hypothesis.
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